Testing a gentler dose for a powerful lung cancer drug
NCT ID NCT05037331
Summary
This study is testing if taking a lower dose of the targeted lung cancer drug osimertinib every other day is still effective and possibly easier for patients to tolerate. It is for adults with a specific type of advanced lung cancer (EGFR-positive NSCLC) who have not had prior treatment with this class of drugs. Researchers will closely monitor how well the cancer responds and track any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
National University Hospital
RECRUITINGSingapore, Singapore
Contact
Contact
Conditions
Explore the condition pages connected to this study.